181 related articles for article (PubMed ID: 31266770)
1. Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
Hundeyin M; Kurz E; Mishra A; Rossi JAK; Liudahl SM; Leis KR; Mehrotra H; Kim M; Torres LE; Ogunsakin A; Link J; Sears RC; Sivagnanam S; Goecks J; Islam KMS; Dolgalev I; Savadkar S; Wang W; Aykut B; Leinwand J; Diskin B; Adam S; Israr M; Gelas M; Lish J; Chin K; Farooq MS; Wadowski B; Wu J; Shah S; Adeegbe DO; Pushalkar S; Vasudevaraja V; Saxena D; Wong KK; Coussens LM; Miller G
Cancer Discov; 2019 Sep; 9(9):1288-1305. PubMed ID: 31266770
[TBL] [Abstract][Full Text] [Related]
2. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
3. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
5. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
6. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
[TBL] [Abstract][Full Text] [Related]
8. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Schmitt TM; Hulbert A; Brockenbrough JS; Nguyen H; Cuevas C; Dotson AM; Tan X; Hotes JL; Greenberg PD; Hingorani SR
Cancer Cell; 2015 Nov; 28(5):638-652. PubMed ID: 26525103
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.
Daley D; Mani VR; Mohan N; Akkad N; Pandian GSDB; Savadkar S; Lee KB; Torres-Hernandez A; Aykut B; Diskin B; Wang W; Farooq MS; Mahmud AI; Werba G; Morales EJ; Lall S; Wadowski BJ; Rubin AG; Berman ME; Narayanan R; Hundeyin M; Miller G
J Exp Med; 2017 Jun; 214(6):1711-1724. PubMed ID: 28442553
[TBL] [Abstract][Full Text] [Related]
10. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
11. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
12. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
13. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
[TBL] [Abstract][Full Text] [Related]
15. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
16. γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.
Daley D; Zambirinis CP; Seifert L; Akkad N; Mohan N; Werba G; Barilla R; Torres-Hernandez A; Hundeyin M; Mani VRK; Avanzi A; Tippens D; Narayanan R; Jang JE; Newman E; Pillarisetty VG; Dustin ML; Bar-Sagi D; Hajdu C; Miller G
Cell; 2016 Sep; 166(6):1485-1499.e15. PubMed ID: 27569912
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Jindal V; Arora E; Masab M; Gupta S
Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
[TBL] [Abstract][Full Text] [Related]
18. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.
Seifert L; Werba G; Tiwari S; Giao Ly NN; Nguy S; Alothman S; Alqunaibit D; Avanzi A; Daley D; Barilla R; Tippens D; Torres-Hernandez A; Hundeyin M; Mani VR; Hajdu C; Pellicciotta I; Oh P; Du K; Miller G
Gastroenterology; 2016 Jun; 150(7):1659-1672.e5. PubMed ID: 26946344
[TBL] [Abstract][Full Text] [Related]
19. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.
Wang W; Marinis JM; Beal AM; Savadkar S; Wu Y; Khan M; Taunk PS; Wu N; Su W; Wu J; Ahsan A; Kurz E; Chen T; Yaboh I; Li F; Gutierrez J; Diskin B; Hundeyin M; Reilly M; Lich JD; Harris PA; Mahajan MK; Thorpe JH; Nassau P; Mosley JE; Leinwand J; Kochen Rossi JA; Mishra A; Aykut B; Glacken M; Ochi A; Verma N; Kim JI; Vasudevaraja V; Adeegbe D; Almonte C; Bagdatlioglu E; Cohen DJ; Wong KK; Bertin J; Miller G
Cancer Cell; 2018 Nov; 34(5):757-774.e7. PubMed ID: 30423296
[TBL] [Abstract][Full Text] [Related]
20. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
